Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...

The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

Merck said it will buy Verona Pharma for $10 billion to bolster its lung-disease business and help replace the expected loss ...

The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older ...